Price Alert

Phathom Pharmaceuticals I... (PHAT)

NASDAQ: PHAT · Real-Time Price · USD

12.21

0.39 (3.30%)

At close: Oct 03, 2025, 3:59 PM

12.45

1.97%

After-hours: Oct 03, 2025, 07:47 PM EDT

Phathom Pharmaceuticals Statistics

Share Statistics

Phathom Pharmaceuticals has 70.94M shares outstanding. The number of shares has increased by 3.75% in one year.

Shares Outstanding	70.94M
Shares Change (YoY)	3.75%
Shares Change (QoQ)	1.62%
Owned by Institutions (%)	78.61%
Shares Floating	39.63M
Failed to Deliver (FTD) Shares	9,929
FTD / Avg. Volume	0.78%

Short Selling Information

The latest short interest is 14M, so 19.73% of the outstanding shares have been sold short.

Short Interest	14M
Short % of Shares Out	19.73%
Short % of Float	32.58%
Short Ratio (days to cover)	12.11

Valuation Ratios

The PE ratio is -1.53 and the forward PE ratio is -38.13. Phathom Pharmaceuticals's PEG ratio is -0.04.

PE Ratio	-1.53
Forward PE	-38.13
PS Ratio	9.28
Forward PS	2.7
PB Ratio	-2.02
P/FCF Ratio	-1.92
PEG Ratio	-0.04

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Phathom Pharmaceuticals.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 4.2, with a Debt / Equity ratio of -2.19.

Current Ratio	4.2
Quick Ratio	4.16
Debt / Equity	-2.19
Debt / EBITDA	-2.12
Debt / FCF	-2.08
Interest Coverage	-3.85

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$129.4K
Profits Per Employee	$-782.96K
Employee Count	427
Asset Turnover	0.15
Inventory Turnover	2.49

Taxes

Income Tax	n/a
Effective Tax Rate	0%

Stock Price Statistics

The stock price has increased by -29.22% in the last 52 weeks. The beta is 0.43, so Phathom Pharmaceuticals's price volatility has been higher than the market average.

Beta	0.43
52-Week Price Change	-29.22%
50-Day Moving Average	10.97
200-Day Moving Average	7.46
Relative Strength Index (RSI)	56.82
Average Volume (20 Days)	1,275,702

Income Statement

In the last 12 months, Phathom Pharmaceuticals had revenue of 55.25M and earned -334.33M in profits. Earnings per share was -5.29.

Revenue	55.25M
Gross Profit	47.28M
Operating Income	-277.47M
Net Income	-334.33M
EBITDA	-261.52M
EBIT	-262.32M
Earnings Per Share (EPS)	-5.29

Full Income Statement

Balance Sheet

The company has 297.26M in cash and 554.95M in debt, giving a net cash position of -257.69M.

Cash & Cash Equivalents	297.26M
Total Debt	554.95M
Net Cash	-257.69M
Retained Earnings	-1.26B
Total Assets	250.22M
Working Capital	127.05M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -266.77M and capital expenditures 0, giving a free cash flow of -266.9M.

Operating Cash Flow	-266.77M
Capital Expenditures	n/a
Free Cash Flow	-266.9M
FCF Per Share	-4.22

Full Cash Flow Statement

Margins

Gross margin is 85.57%, with operating and profit margins of -502.18% and -605.09%.

Gross Margin	85.57%
Operating Margin	-502.18%
Pretax Margin	-605.09%
Profit Margin	-605.09%
EBITDA Margin	-473.33%
EBIT Margin	-502.18%
FCF Margin	-483.07%

Dividends & Yields

PHAT does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

The average price target for PHAT is $17, which is 39.2% higher than the current price. The consensus rating is "Buy".

Price Target	$17
Price Target Difference	39.2%
Analyst Consensus	Buy
Analyst Count	5

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	-9.62
Piotroski F-Score	3